Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.
Frequently asked questions
What sector does ITRMF (ITRMF) operate in?
ITRMF belongs to the Other sector and operates in the Biotechnology industry.
What is ITRMF (ITRMF) current stock price?
As of the latest data, ITRMF stock price is $0.03, with a previous close of $0.03.
What is ITRMF (ITRMF) current market capitalization?
ITRMF market cap is approximately 1.65 million.
What is ITRMF (ITRMF) Earnings Per Share (EPS)?
The trailing EPS is -$7.20, and the forward EPS is -$0.24.
Does ITRMF (ITRMF) pay dividends?
No. ITRMF does not pay a dividend.
What is ITRMF (ITRMF) beta (volatility) score?
ITRMF has a beta of 3.824, indicating very high volatility compared to the market.